Sintilimab versus docetaxel as second-line treatment in advanced or metastatic squamous non-small-cell lung cancer: an open-label, randomized controlled phase 3 trial (ORIENT-3)
信迪利单抗与多西他赛作为晚期或转移性鳞状非小细胞肺癌二线治疗的比较：一项开放标签、随机对照的3期试验（ORIENT-3）
期刊:Cancer Communications
影响因子:24.9
doi:10.1002/cac2.12385
Shi, Yuankai; Wu, Lin; Yu, Xinmin; Xing, Puyuan; Wang, Yan; Zhou, Jianying; Wang, Airong; Shi, Jianhua; Hu, Yi; Wang, Ziping; An, Guangyu; Fang, Yong; Sun, Sanyuan; Zhou, Caicun; Wang, Changli; Ye, Feng; Li, Xingya; Wang, Junye; Wang, Mengzhao; Liu, Yunpeng; Zhao, Yanqiu; Yuan, Ying; Feng, Jifeng; Chen, Zhendong; Shi, Jindong; Sun, Tao; Wu, Gang; Shu, Yongqian; Guo, Qisen; Zhang, Yi; Song, Yong; Zhang, Shucai; Chen, Yuan; Li, Wei; Niu, Hongrui; Hu, Wenwei; Wang, Lijun; Huang, Jianan; Zhang, Yang; Cheng, Ying; Wu, Zhengdong; Peng, Bo; Sun, Jiya; Mancao, Christoph; Wang, Yanqi; Sun, Luyao
